Janssens Study For Nipocalimab As Indicated For Eos Hdfn Published In The New England Journal Of Medicine

Janssen's Nipocalimab Tackles Hemolytic Disease of the Fetus and Newborn

Phase 2 Study Results Announced

WEB SPRING HOUSE Pa August 7 2024 Johnson Johnson today announced the results from the Phase 2 open-label.

WEB IVIG is used in some cases of early-onset severe HDFN on the basis in part of its competitive FcRn.

About Nipocalimab

Nipocalimab is a fully human IgG monoclonal antibody blocking neonatal Fc receptor FcRn.

WEB SPRING HOUSE PENNSYLVANIA February 6 2023 Nipocalimab is anticipated to be used for hemolytic disease of the fetus and newborn.

WEB SPRING HOUSE PENNSYLVANIA JUNE 26 2023 Nipocalimab lowers transplacental IgG transfer.

WEB Nipocalimab an anti-neonatal Fc receptor blocker inhibits transplacental IgG transfer and lowers.

Conclusion

The Phase 2 results show that nipocalimab is a promising treatment for hemolytic disease of the fetus and newborn.

Further studies are needed to confirm the efficacy and safety of nipocalimab in a larger population.